동물용 신약 개발용 AI 시장 : 시장 분석 및 예측 유형별, 제품별, 서비스별, 기술별, 용도별, 컴포넌트별, 최종 사용자별, 온프레미스별, 단계별, 솔루션별

AI in Veterinary Drug Discovery Market is anticipated to expand from $1.5 billion in 2024 to $5.8 billion by 2034, growing at a CAGR of approximately 14.5%. The AI in Veterinary Drug Discovery Market leverages artificial intelligence to enhance the efficiency and accuracy of drug development for animal health. This market encompasses AI-driven platforms that streamline target identification, lead optimization, and predictive modelling. With the rising demand for innovative veterinary therapeutics, AI technologies are pivotal in reducing time-to-market and enhancing the precision of drug discovery processes, fostering advancements in animal healthcare solutions.

The AI in Veterinary Drug Discovery Market is evolving rapidly, driven by the need for efficient and innovative drug development processes. The machine learning algorithms segment is the top performer, revolutionizing drug discovery by predicting outcomes and optimizing compound selection. Within this segment, deep learning models are particularly impactful, providing nuanced insights into complex biological data. The second highest performing segment is natural language processing (NLP), which enhances data analysis by extracting valuable information from vast scientific literature. NLP's ability to streamline research is crucial for accelerating drug discovery timelines. In terms of sub-segments, the compound screening sub-segment leads in performance, leveraging AI to identify promising drug candidates with higher precision. The drug repurposing sub-segment follows, offering cost-effective solutions by finding new uses for existing drugs. Together, these advancements underscore the transformative potential of AI in veterinary medicine, promising significant improvements in drug efficacy and development speed.

Market Snapshot:

The AI in Veterinary Drug Discovery Market is witnessing a dynamic shift in market share, with emerging players making significant inroads. The pricing landscape remains competitive, reflecting the balance between innovation and affordability. New product launches are frequent, driven by technological advancements and the growing demand for efficient drug discovery processes. The market is characterized by a robust pipeline of AI-driven solutions, offering enhanced capabilities in drug discovery and development. Competition benchmarking reveals a diverse array of players, ranging from established pharmaceutical giants to nimble startups. Regulatory influences are pivotal, with stringent guidelines in North America and Europe shaping the competitive landscape. The market is further influenced by government initiatives promoting AI integration in veterinary sciences. As companies strive to gain a competitive edge, strategic partnerships and collaborations are on the rise. The market outlook is optimistic, with AI technologies poised to revolutionize veterinary drug discovery, offering unprecedented opportunities for growth and innovation.

Geographical Overview:

The AI in veterinary drug discovery market is witnessing substantial growth across various regions, each exhibiting unique characteristics. North America leads the charge, propelled by advanced AI technologies and significant investments in veterinary research. The region's robust infrastructure and strong collaborations between tech firms and veterinary institutions are key drivers. Europe is making strides with a focus on innovation and sustainability in veterinary drug development. The region's regulatory environment and emphasis on animal welfare encourage the adoption of AI-driven solutions. Asia Pacific is emerging as a promising market, driven by a surge in pet ownership and rising demand for veterinary care. Countries like China and India are investing heavily in AI technologies, fostering a dynamic ecosystem for veterinary drug discovery. Latin America and the Middle East & Africa are nascent markets with growing potential. These regions are recognizing AI's transformative role in enhancing veterinary healthcare, paving the way for future growth.

Key Trends and Drivers:

The AI in Veterinary Drug Discovery Market is experiencing robust growth. This is driven by technological advancements and increasing demand for innovative veterinary therapeutics. Key trends include the integration of AI with big data analytics, which accelerates drug discovery processes by identifying potential compounds more efficiently. AI-driven platforms are enabling precise predictions of drug efficacy and safety, reducing the reliance on traditional trial-and-error methods. Moreover, there is a growing emphasis on personalized veterinary medicine, where AI tools are tailored to develop species-specific and condition-specific drugs. This enhances treatment outcomes and animal welfare. Another driver is the rising incidence of zoonotic diseases, prompting the need for rapid drug development. The veterinary sector is increasingly adopting AI to streamline regulatory compliance and expedite the approval process. Additionally, partnerships between tech companies and veterinary pharmaceutical firms are fostering innovation. Opportunities abound in developing AI solutions that address unmet needs in animal health, particularly in emerging markets where veterinary infrastructure is evolving.

Restraints and Challenges:

The AI in Veterinary Drug Discovery Market encounters several notable restraints and challenges. A significant restraint is the high cost of AI technology deployment, which can be prohibitive for smaller firms and startups. This financial barrier limits innovation and the widespread adoption of AI solutions in veterinary drug discovery. Additionally, there is a scarcity of skilled professionals with expertise in both AI and veterinary sciences. This skill gap hampers the development and integration of AI-driven solutions. Another challenge is the regulatory landscape, which is often complex and varies significantly across regions, leading to delays in product development and market entry. Data privacy and security concerns also pose challenges, as the handling of sensitive data requires robust systems to prevent breaches. Lastly, the lack of standardized protocols for AI implementation in veterinary drug discovery can lead to inconsistent outcomes, further complicating the market's growth potential.

Key Players:

Insilico Medicine, Atomwise, Cyclica, Deep Genomics, BenevolentAI, Exscientia, Healx, Valo Health, Standigm, twoXAR, Aitia, Numerate, Aria Pharmaceuticals, BioSymetrics, Verge Genomics

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Component
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Stage
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Machine Learning
  • 4.1.2 Deep Learning
  • 4.1.3 Natural Language Processing
  • 4.1.4 Computer Vision
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Software Tools
  • 4.2.2 AI Platforms
  • 4.2.3 AI Services
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting
  • 4.3.2 Integration and Deployment
  • 4.3.3 Support and Maintenance
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Cloud-based
  • 4.4.2 On-premises
  • 4.4.3 Hybrid
  • 4.4.4 Edge AI
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Drug Discovery
  • 4.5.2 Diagnostics
  • 4.5.3 Precision Medicine
  • 4.5.4 Clinical Trials
• 4.6 Market Size & Forecast by Component (2020-2035)
  • 4.6.1 Hardware
  • 4.6.2 Software
  • 4.6.3 Services
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Research Institutes
  • 4.7.2 Pharmaceutical Companies
  • 4.7.3 Biotechnology Firms
  • 4.7.4 Veterinary Clinics
  • 4.7.5 Academic Institutions
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 Cloud
  • 4.8.2 On-premise
  • 4.8.3 Hybrid
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Discovery
  • 4.9.2 Preclinical
  • 4.9.3 Clinical
  • 4.9.4 Approval
  • 4.9.5 Post-market Surveillance
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Predictive Analytics
  • 4.10.2 Image Recognition
  • 4.10.3 Genomics
  • 4.10.4 Proteomics

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Component
    • 5.2.1.7 End User
    • 5.2.1.8 Deployment
    • 5.2.1.9 Stage
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Component
    • 5.2.2.7 End User
    • 5.2.2.8 Deployment
    • 5.2.2.9 Stage
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Component
    • 5.2.3.7 End User
    • 5.2.3.8 Deployment
    • 5.2.3.9 Stage
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Component
    • 5.3.1.7 End User
    • 5.3.1.8 Deployment
    • 5.3.1.9 Stage
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Component
    • 5.3.2.7 End User
    • 5.3.2.8 Deployment
    • 5.3.2.9 Stage
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Component
    • 5.3.3.7 End User
    • 5.3.3.8 Deployment
    • 5.3.3.9 Stage
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Component
    • 5.4.1.7 End User
    • 5.4.1.8 Deployment
    • 5.4.1.9 Stage
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Component
    • 5.4.2.7 End User
    • 5.4.2.8 Deployment
    • 5.4.2.9 Stage
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Component
    • 5.4.3.7 End User
    • 5.4.3.8 Deployment
    • 5.4.3.9 Stage
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Component
    • 5.4.4.7 End User
    • 5.4.4.8 Deployment
    • 5.4.4.9 Stage
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Component
    • 5.4.5.7 End User
    • 5.4.5.8 Deployment
    • 5.4.5.9 Stage
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Component
    • 5.4.6.7 End User
    • 5.4.6.8 Deployment
    • 5.4.6.9 Stage
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Component
    • 5.4.7.7 End User
    • 5.4.7.8 Deployment
    • 5.4.7.9 Stage
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Component
    • 5.5.1.7 End User
    • 5.5.1.8 Deployment
    • 5.5.1.9 Stage
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Component
    • 5.5.2.7 End User
    • 5.5.2.8 Deployment
    • 5.5.2.9 Stage
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Component
    • 5.5.3.7 End User
    • 5.5.3.8 Deployment
    • 5.5.3.9 Stage
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Component
    • 5.5.4.7 End User
    • 5.5.4.8 Deployment
    • 5.5.4.9 Stage
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Component
    • 5.5.5.7 End User
    • 5.5.5.8 Deployment
    • 5.5.5.9 Stage
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Component
    • 5.5.6.7 End User
    • 5.5.6.8 Deployment
    • 5.5.6.9 Stage
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Component
    • 5.6.1.7 End User
    • 5.6.1.8 Deployment
    • 5.6.1.9 Stage
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Component
    • 5.6.2.7 End User
    • 5.6.2.8 Deployment
    • 5.6.2.9 Stage
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Component
    • 5.6.3.7 End User
    • 5.6.3.8 Deployment
    • 5.6.3.9 Stage
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Component
    • 5.6.4.7 End User
    • 5.6.4.8 Deployment
    • 5.6.4.9 Stage
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Component
    • 5.6.5.7 End User
    • 5.6.5.8 Deployment
    • 5.6.5.9 Stage
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Insilico Medicine
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Atomwise
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Cyclica
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Deep Genomics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 BenevolentAI
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Exscientia
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Healx
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Valo Health
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Standigm
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 twoXAR
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Aitia
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Numerate
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Aria Pharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 BioSymetrics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Verge Genomics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us